Published in Women's Health Weekly, September 13th, 2001
Approximately 15 subjects will be evaluated in each of the two trials. Each trial will run 30 days and will measure blood levels of levonorgestrel and ethinyl estradiol. When these trials are completed, Phase II trials will begin with each formula to determine ability to inhibit ovulation.
Agile Therapeutics currently is conducting two Phase II trials using its original formulation in 7.5 cm2 and 9...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly